Adults taking Eli Lilly's Zepbound lost 47% more weight on average than those on Novo Nordisk's Wegovy, Lilly reported from ...
One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...
Eli Lilly (LLY) announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Zepbound ...
Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.
Eli Lilly ( LLY 0.91%) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 ...
Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical ...
Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market ...